The Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month.
Key Takeaways
- A new China government R&D support program will focus on four major chronic disease areas with high prevalence in China – cardiovascular, respiratory and metabolic diseases and malignant tumors.
Th fresh state-supported effort will be focused primarily on four major chronic conditions with a high prevalence in China –...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?